CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Dehradun’s Top Diagnostic Chain Sold for Rs 35 Crore in Major North India Expansion Move
DSIJ Intelligence
/ Categories: Trending, Mindshare

Dehradun’s Top Diagnostic Chain Sold for Rs 35 Crore in Major North India Expansion Move

Deal Marks Strategic Step to Strengthen Presence Across Tier-2 Cities in the Region

Metropolis Healthcare Limited, one of India’s top diagnostic chains, has announced the acquisition of Dr. Ahujas’ Pathology & Imaging Centre (DAPIC), Dehradun’s leading diagnostic player. The deal was signed through its wholly owned subsidiary, Metropolis Histoxpert Digital Services. The all-cash deal is valued at Rs 35.01 crore, and Metropolis will gain 100 per cent ownership of DAPIC.

About Dr. Ahujas’ Pathology & Imaging Centre
 DAPIC was founded in 1990 by Dr. Alok Ahuja and Dr. Alka Ahuja. It operates two NABL and NABH accredited labs, 11 patient service centres, and nine hospital-based centres in Uttarakhand. It offers pathology and radiology services such as ultrasound, ECG, and X-ray. In FY25, DAPIC posted estimated revenue of Rs 11.5 crore, with 73 per cent coming from pathology and 27 per cent from radiology. About 80 per cent of its business comes from walk-in patients, giving it strong B2C reach.

Strategic Fit for Metropolis
This acquisition is part of Metropolis’ 'String of Pearls' strategy to expand its regional presence. Previous acquisitions in North India include Core Diagnostics and Scientific Pathology. With the addition of DAPIC, the North India contribution to overall revenue has grown from 8 per cent to nearly 15 per cent. Metropolis plans to expand further across Uttar Pradesh and Uttarakhand.

Future Plans and Integration
Dr. Ahuja and Dr. Alka Ahuja will continue with the business during the transition. Metropolis now becomes the second-largest diagnostic chain in Uttarakhand. The company plans to expand accessibility using a franchise model and strengthen both B2C and B2B offerings with a wider test portfolio.

Advisors Involved
EY acted as the exclusive financial advisor to DAPIC, while BDO India LLP advised Metropolis Healthcare in the transaction.

Disclaimer: The article is for informational purposes only and not investment advice.

Previous Article Markets Crash: Sensex Tanks 2,291 Points, Nifty Suffers Worst Fall in 10 Months and Witness Highest Volume in 5 Months
Next Article Over 9,000 Per cent Returns: Kolkata Based Fast-Growing Solar Cell Maker Secures 100 MW Solar Cell Supply Order to Accelerate Expansion Plans in 2025-26
Print
102 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR